Table 5. Multivariate Analysis of Progression-Free Survival.
| Variable | Ad, EGFR mt (-) |
P | NSCLC, EGFR mt (+) |
P | SQ |
P |
|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | ||||
| Age, years | ||||||
| < 70 | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||
| ≥ 70 | 1.06 (0.77 - 1.47) | 0.72 | 1.07 (0.72 - 1.61) | 0.73 | 1.16 (0.74 - 1.83) | 0.52 |
| Smoking history | ||||||
| Non-smoker | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||
| Smoker | 1.02 (0.66 - 1.56) | 0.94 | 1.06 (0.72 - 1.56) | 0.78 | 1.17 (0.52 - 2.62) | 0.71 |
| No. of metastatic sites | ||||||
| < 2 | 1 (Reference) | 1.41 (0.90 - 2.19) | 0.13 | 1 (Reference) | ||
| ≥ 2 | 1.01 (0.74 - 1.39) | 0.95 | 1.24 (0.78 - 1.98) | 0.36 | ||
| ECOG-PS | ||||||
| 0 or 1 | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||
| ≥ 2 | 1.95 (1.31 - 2.90) | < 0.01 | 1.63 (0.99 - 2.71) | 0.057 | 1.57 (0.92 - 2.69) | 0.10 |
| Bevacizumab-containing | ||||||
| Yes | 1 (Reference) | |||||
| No | 1.38 (0.93 - 2.05) | 0.12 | ||||
| Line of EGFR-TKI | ||||||
| First-line | 1 (Reference) | |||||
| Second or later line | 1.58 (0.99 - 2.52) | 0.054 | ||||
| PTX or nab-PTX-containing | ||||||
| Yes | 1 (Reference) | |||||
| No | 1.30 (0.83 - 2.04) | 0.25 | ||||
| GRIm-Score | ||||||
| Low | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||
| High | 1.25 (0.85 - 1.82) | 0.25 | 1.89 (1.00 - 3.55) | 0.049 | 1.10 (0.66 - 1.83) | 0.71 |
Ad: adenocarcinoma; CI: confidence interval; ECOG-PS: Eastern Cooperative Oncology Group performance status; EGFR: epidermal growth factor receptor; HR: hazard ratio; LIPI: lung immune prognostic index; nab-PTX: nanoparticle albumin-bound paclitaxel; NSCLC: non-small cell carcinoma; SQ: squamous cell carcinoma; TKI: tyrosine kinase inhibitor.